(Health Korea News / Yu Ji-in) Hanmi Pharmaceutical announced on the 5th that it plans to participate in a number of global academic conferences in the second half of this year and present research results on innovative new drugs under development. The company plans to expand its innovation power based on its new modalities, continue to introduce new pipelines, and further strengthen its global R&D competitiveness.
There are a total of 13 research projects that Hanmi Pharmaceutical plans to announce in the second half of the year. Specifically, they include ▲short bowel syndrome treatment ‘LAPS GLP-2 analog (HM15912)’ ▲EZH1/2 dual inhibitor (HM97662) ▲p53 mRNA anticancer new drug ▲KRAS mRNA anticancer vaccine ▲MAT2A inhibitor ▲selective HER2 exon 20 insertion mutation inhibitor ▲SOS1 inhibitor (HM99462) ▲HOP project ‘new concept obesity treatment’ ▲obesity treatment triple agent ‘LA-GLP/GIP/GCG (HM15275)’ ▲immunomodulatory anticancer agent ‘LAPS IL-2 analog (HM16390)’ ▲PD-L1/4-1BB dual antibody immunotherapy (BH3120) ▲congenital hyperinsulinemia treatment ‘efegreg glucagon (HM15136)’ ▲acute myeloid leukemia treatment ‘tuspetinib’, etc.
Researchers from Hanmi Pharmaceutical’s R&D Center and clinical team will attend in large numbers to explain the presentation content and introduce innovative tasks.
A Hanmi Pharmaceutical official said, “In the second half of the year, the ‘new concept obesity treatment’ that has been developed as a private pipeline of the HOP project and the ‘MAT2A inhibitor,’ a new anticancer pipeline, are expected to receive a lot of attention as they will be revealed for the first time.”
Hanmi Pharmaceutical will present the clinical pharmacokinetic results of the phase 1 clinical trial of ‘Laps GLP-2 Analog (HM15912),’ a treatment for short bowel syndrome that is being developed as the world’s first once-monthly dosage form, in patients with impaired renal function at the European Society of Clinical Nutrition and Metabolism (ESPEN) to be held in September.
In September, the European Society for Medical Oncology (ESMO) and the International Society for Drug Research (ISSX) will present the clinical background, design, and non-clinical study results of the ‘next-generation EZH1,2 dual inhibitor (HM97662)’ currently under development as a new targeted anticancer innovative drug. ‘HM97662’, which simultaneously inhibits EZH2 and EZH1, a type of enzyme that causes various solid cancers as well as hematological cancers such as malignant lymphoma, is expected to show stronger efficacy than anticancer drugs with a single EZH2 inhibition mechanism and also be able to overcome resistance.
Research results utilizing the new modality are scheduled to be presented at the Society for Gene and Cell Therapy (ESGCT) in October. Hanmi Pharmaceutical plans to demonstrate the possibility of developing next-generation drugs by presenting research results on a ‘p53 mRNA anticancer drug’ targeting p53 mutant cancer and a ‘KRAS mRNA anticancer vaccine’ targeting various KRAS mutations using mRNA platform technology.
The new anticancer pipeline, ‘MAT2A inhibitor’, which has not been disclosed until now, will be revealed for the first time at the EORTC-NCI-AACR, an international cancer conference in October. ‘MAT2A inhibitor’ is an anticancer new drug that acts on the ‘synthetic lethality principle’, and is a treatment targeting cancer types in which the MTAP (methylthioadenosine phosphorylase) gene, which plays an important role in a specific metabolic pathway within cells, has been deleted.
EORTC-NCI-AACR will also present the research results of a ‘selective HER2 exon 20 insertion mutation inhibitor’ that selectively targets HER2 exon 20 insertion mutation and HER2 amplification/overexpression to minimize side effects, and a ‘SOS1 inhibitor (HM99462)’ that targets fatal KRAS mutation among genetic mutations that cause cancer.
Hanmi Pharm will unveil for the first time the target and non-clinical research results of an obesity treatment candidate substance that has been developed as a private pipeline of the HOP project at the American Society for Obesity Week in November. The company explains that the substance is a “new concept obesity treatment” that can simultaneously bring about weight loss and muscle gain effects with a completely different mechanism of action from incretin.
In addition, this conference will also present the follow-up nonclinical study results of the next-generation obesity treatment triple-action agent ‘LA-GLP, GIP, GCG (HM15275)’, which was first disclosed at the American Diabetes Association (ADA) last June.
‘HM15275’, which is expected to have a weight loss effect of more than 25% while minimizing muscle loss, is specialized in the treatment of obesity by optimizing the action of each of the three receptors: glucagon-like peptide-1 (GLP-1), gastric inhibitory peptide (GIP), and glucagon (GCG), and is characterized by being designed to be effective in various metabolic diseases in addition.
In November, the Society for Immunotherapy of Cancer (SITC) will announce the non-clinical results of the innovative new immune-regulating anticancer drug ‘LAPS IL-2 Analog (HM16390)’ that proved ‘complete remission’ where all malignant tumors disappear, and will disclose the clinical background and design of the next-generation immune anticancer drug ‘BH3120’ that applies the independently developed dual antibody platform technology ‘Pentambody’.
In November, the European Society of Pediatric Endocrinology (ESPE) will announce partial results of a phase 2 clinical trial targeting pediatric and adult patients for ‘Effeger glucagon (HM15136),’ an innovative new drug being developed by Hanmi Pharmaceutical for the treatment of congenital hyperinsulinemia.
Hanmi Pharmaceutical will also attend the American Society of Hematology (ASH) in December and present clinical results supporting the possibility of triple combination therapy with the innovative new drug ‘Tuspetinib’ for the treatment of acute myeloid leukemia (AML). In addition, the schedule for overseas academic conference presentations, which has not yet been confirmed, will be announced later.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
